Patent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
This patent provides intellectual property protection for the ongoing human trial that evaluates the effect of the combination of GR-MD-02 with approved cancer immunotherapy drugs. Results of the first cohort of the Phase 1b study of a galectin inhibitor (GR-MD-02) and pembrolizumab (KEYTRUDA®) in patients with metastatic melanoma were reported earlier this year, and now Galectin reports that the second cohort of three patients treated with 4 mg/kg of GR-MD-02 has been completed, and the third cohort of 10 patients treated with 8 mg/kg will begin enrollment after the patients in the second cohort have completed 85 days of protocol, as per
Additionally, the patent covers the ability of GR-MD-02 to enhance the effectiveness of immune modulators in a variety of cancers, including gastrointestinal cancer, pancreatic cancer, bile duct cancer, sarcoma, myosarcoma, breast cancer, lung cancer, head and neck cancer, mouth cancer, skin cancer, melanoma, kidney cancer, urinary tract cancer, prostate cancer, testicular cancer, ovarian cancer, endometrial cancer, neurological cancer, endocrine gland cancer, bone cancer, hematological cancers, multiple myeloma, and myelofibrosis. The patent coverage extends through 2033.
"This patent protects our ability to use GR-MD-02 to enhance the effectiveness of multiple classes of immune modulators, in the treatment of a wide range of cancers," said
With this patent, the Company now holds 17 granted
GR-MD-02, a Non-Biological Complex Drug (NBCD), is a proprietary polysaccharide pharmaceutical preparation that inhibits galectin proteins. In addition to the Combination Immunotherapy cancer trials, GR-MD-02 is currently being studied in a Phase 2b clinical trial in subjects with NASH cirrhosis. Additionally, GR-MD-02 has been studied and shown encouraging preliminary results in two, open-label Phase 2a trials in patients with severe skin diseases, including moderate-to-severe plaque psoriasis and atopic dermatitis.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for GR-MD-02 will lead to the first therapy for the treatment of
fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in connection with cancer immunotherapy. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of its other drugs in development; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its
development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended
Galectin Therapeutics, Inc. Jack Callicutt, Chief Financial Officer 678-620-3186 email@example.com
News Provided by Acquire Media